NASHVILLE, Tenn., May 26, 2021 /PRNewswire/ -- OneOncology, the platform for independent oncology practices, said today that partner practice physicians and other OneOncology experts will make 23 presentations across 12 different subject categories at the 2021 ASCO Annual Meeting from June 4-6.
Lee Schwartzberg, MD, Chief Medical Officer, OneOncology, is an author on six abstracts and Axel Grothey, MD, Medical Director, OneR, Director of GI Cancer Research at the West Cancer Center, is the author on 12 abstracts. OneR is OneOncology's clinical trial site management organization launched last year.
Drs. Grothey, Schwartzberg and Ari VanderWalde, Medical Director of Precision Oncology at OneR and Director of Research at West Cancer Center are authors on an abstract evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response as part of Genentech's basket clinical trial, MyTACTIC. The trial aims to match patient populations with a targetable genomic alteration to a specific investigational agent. Dr. Grothey is the lead author on the abstract.
West Cancer Center investigator, Daniel Vaena, MD, is the lead author of an abstract selected for oral presentation. Dr. Vaena's abstract presentation will discuss the results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies.
Another highlight amongst the body of research presented at ASCO is an abstract that examines the impact of clinical trial enrollment on episode costs in Medicare's Oncology Care Model. Garrett Young, Director, Clinical & Strategic Analytics, OneOncology is the lead author on this abstract selected for a poster discussion in the Health Services Research and Quality Improvement category. Being selected for a poster discussion recognizes the abstract as one of the top 12 in the topic area.
Originally published by OneOncology >>